December 11, 2025 |
At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright’s HEOR Theater presentation ‘MFN Pricing: More Fun to Navigate – A European Roadmap to Success,’ with potentially over a hundred individuals missing out on the chance to learn more about how to prepare for most-favored nation pricing.
Due to its popularity and the ever-changing nature of this vital topic, Genesis Research Group has teamed up with The Evidence Base to review and update the presentation in the light of recent developments.

During the original presentation, Tim Wright, EVP, Access & Pricing at Genesis Research Group, outlined a practical roadmap for navigating MFN pricing, from establishing a U.S. anchor price and applying value-based approaches to mitigating European price erosion risks. The session offered valuable insights for market access professionals seeking to balance policy pressures with innovative pricing strategies.
In a newly recorded interview with The Evidence Base, Tim presents an updated version of his presentation plus commentary on the latest most-favored nation pricing developments. Tim breaks down:
– A recap of the original session: “MFN Pricing: ‘More Fun to Navigate’ – A European Roadmap to Success”
– The GENEROUS Model in relation to MFN
– How MFN and the IRA differ—and where they intersect
– Advice and practical steps to prepare for MFN activities
To access this timely resource for pricing, market access, and HEOR professionals navigating rapidly shifting policy landscapes, visit The Evidence Base.
If you have questions or would like a meeting to discuss, you can contact Tim via solutions@genesisrg.com.
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence…
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it…
With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it’s a lot to digest. In a new…
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on…
At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright’s HEOR Theater presentation ‘MFN Pricing: More Fun to Navigate – A European Roadmap to Success,’ with potentially…
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10…
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation…
HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.
Genesis Research Group, a leading provider of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the appointment of Tim Wright as Executive Vice…
In the rapidly evolving landscape of healthcare and pharmaceutical market access, data analytics has become a critical component for making informed decisions. We sat down with Ki Park, our Vice…
